Multi-center evaluation of a commercial Kit for tacrolimus determination by LC/MS/MS

Clinical Biochemistry

Volumn 43, Issue 10-11, 2010, Pages 910-920

  Napoli, Kimberly L ^a   Hammett Stabler, Catherine ^b   Taylor, Paul J ^c   Lowe, Webb ^b   Franklin, Michael E ^c   Morris, Michael R ^d   Cooper, Donald P ^d  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

^d WATERS CORPORATION   (United States)

Author keywords

Harmonization; HPLC; Tacrolimus; Tandem mass spectrometry; Therapeutic drug monitoring

Indexed keywords

TACROLIMUS; DIAGNOSTIC KIT;

ACCURACY; ANALYTIC METHOD; ARTICLE; BLOOD ANALYSIS; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; HUMAN; INTERMETHOD COMPARISON; KIDNEY GRAFT; LIQUID CHROMATOGRAPHY; LIVER GRAFT; PRIORITY JOURNAL; RELIABILITY; SAMPLING ERROR; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS; ADULT; BLOOD; DIAGNOSTIC KIT; EVALUATION STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MULTICENTER STUDY (TOPIC); PRACTICE GUIDELINE; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL;

ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; KIDNEY TRANSPLANTATION; LINEAR MODELS; LIVER TRANSPLANTATION; MULTICENTER STUDIES AS TOPIC; PRACTICE GUIDELINES AS TOPIC; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; TACROLIMUS; TANDEM MASS SPECTROMETRY;

EID: 77955675038     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.03.016     Document Type: Article

References (45)

1. No authors Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. Transplant Proc 1990, 22:1357-1361.
2. Shaw L.M., Yatscoff R.W., Bowers L.D., et al. Canadian consensus meeting on cyclosporine monitoring: report of the consensus panel. Clin Chem 1990, 36:1841-1846.
3. Jusko W.J., Thomson A.W., Fung J., et al. Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit 1995, 17:606-614.
4. Oellerich M., Armstrong V.W., Kahan B., et al. Lake Louise consensus conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit 1995, 17:642-654.
5. Yatscoff R.W., Boeckx R., Holt D.W., et al. Consensus guidelines of therapeutic drug monitoring of rapamycin: report of the consensus panel. Ther Drug Monit 1995, 17:676-680.
6. Oellerich M., Armstrong V.W., Schütz E., Shaw L.M. Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise consensus conference on cyclosporine and tacrolimus. Clin Biochem 1998, 31:309-316.
7. Tacrolimus I.I. IMx System Package Insert 2003, Abbott Laboratories, Abbott Park, IL.
8. Cyclosporine Monoclonal Whole Blood TDx/TDxFlx Package Insert 2005, Abbott Laboratories, Abbott Park, IL.
9. Sirolimus IMx System Package Insert 2006, Abbott Laboratories, Abbott Park, IL.
10. Emit® 2000 Tacrolimus Assay Dade Behring Package Insert 2003, Syva Company, Cupertino, CA.
11. Taylor P.J. Therapeutic drug monitoring of immunosuppressant drugs by HPLC-mass spectrometry. Ther Drug Monit 2004, 26:215-219.
12. Christians U., Jacobsen W., Serkova N., et al. Automated, fast and sensitive quantification of drugs in blood by liquid chromatography - mass spectrometry with on-line extraction: immunosuppressants. J Chromatog B 2000, 748:41-53.
13. Keevil B.G., McCann S.J., Cooper D.P., Morris M.R. Evaluation of a rapid micro-scale assay for tacrolimus by liquid chromatography-tandem mass spectrometry. Ann Clin Biochem 2002, 39:487-492.
14. Wallemacq P.E., Vanbinst R., Asta S., Cooper D.P. High-throughput liquid chromatography-tandem mass spectrometric analysis of sirolimus in whole blood. Clin Chem Lab Med 2003, 41:921-925.
15. Annesley T.M., Clayton L. Simple extraction protocol for analysis of immunosuppressant drugs in whole blood. Clin Chem 2004, 50:1845-1848.
16. Poquette M.A., Lensmeyer G.L., Doran T.C. Effective use of liquid chromatography-mass spectrometry (LC/MS) in the routine clinical laboratory for monitoring sirolimus, tacrolimus, and cyclosporine. Ther Drug Monit 2005, 27:144-150.
17. Napoli K.L. Is microparticle enzyme-linked immunoassay (MEIA) reliable for use in tacrolimus TDM? Comparison of MEIA to liquid chromatography with mass spectrometric detection using longitudinal trough samples from transplant recipients. Ther Drug Monit 2006, 28:491-504.
18. Napoli K.L. Comparison of 12-hour AUC cyclosporine concentrations determined by liquid chromatography-mass spectrometry and fluorescence polarization immunoassay reveals sirolimus effect on cyclosporine pharmacokinetics. Ther Drug Monit 2006, 28:726-736.
19. Taylor P.J., Brown S.R., Cooper D.P., et al. A high-throughput HPLC-MS/MS method for tacrolimus measurement (abstract). Ther Drug Monit 2005, 27:256.
20. Wilson D.H., Sepe D., Barnes G., Johnston F. Inter-laboratory differences in sirolimus results from six sirolimus testing centers using HPLC tandem mass spectrometry (LC/MS/MS). Clin Chim Acta 2005, 355:211-213.
21. NCCLS Evaluation of Precision Performance of Clinical Chemistry Devices; Approved Guideline NCCLS document EP5-A 2004, NCCLS, Wayne, PA.
22. NCCLS Evaluation of the Linearity of Quantitative Measurement Procedures A Statistical Approach; Approved Guideline NCCLS document EP6-A 2003, NCCLS, Wayne, PA.
23. NCCLS Interference Testing in Clinical Chemistry; Approved Guideline NCCLS document EP7-A 2002, NCCLS, Wayne, PA.
24. NCCLS Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline - Second Edition NCCLS document EP9-A2 2002, NCCLS, Wayne, PA.
25. NCCLS Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline NCCLS document EP17-A 2004, NCCLS, Wayne, PA.
26. Food and Drug Administration, US Department of Health and Human Services; Class II Special Controls Guidance Document: Cyclosporine and Tacrolimus Assays; Guidance for Industry and FDA. Center for Devices and Radiological Health (September 16, 2002), Available at http://www.gov/cder/ode/guidance/1380.html.
27. Nichols J.H., Ratner L.C. Immunosuppressant Drug Monitoring in Standards of Laboratory Practice: Guidelines for Therapeutic Drug Monitoring Services. National Academy of Clinical Biochemistry 1999, 43-49. A. Warner, T. Annesley (Eds.).
28. Shaw L.M., Annesley T.M., Kaplan B., Brayman K.L. Analytical requirements for immunosuppressive drugs in clinical trials. Ther Drug Monit 1995, 17:577-583.
29. CLSI EP9 Method Comparison Report Interpretation Guide. EP Evaluator software, Version 7; copyright David G. Rhoads Associates, Inc., 1991-2005.
30. Streit F., Schütz E., Armstrong V.W., Oellerich M. Quantitation of tacrolimus and five metabolites by API tandem mass spectrometry. Clin Chem 2000, 46:A915.
31. Food and Drug Administration, US Department of Health and Human Services; Guidance for Industry Bioanalytical Method Validation. Center for Drug Evaluation and Research (May 2001) Available at http://www.fda.gov/cder/guidance/4252.pdf.
32. Tacrolimus International Proficiency Testing Scheme (St. George's Hospital, London, UK; , accessed December 22, 2008). http://www.bioanalytics.co.uk.
33. Borrows R., Chusney G., Louicaidou M., et al. Clinical outcomes of renal transplantation using liquid chromatographic monitoring of tacrolimus. Ther Drug Monit 2006, 28:269-273.
34. Prémaud A., Rousseau A., Le Meur Y., et al. Comparison of liquid chromatography-tandem mass spectrometry with a commercial enzyme-multiplied immunoassay for the determination of plasma MPA in renal transplant recipients and consequences for therapeutic drug monitoring. Ther Drug Monit 2004, 26:609-619.
35. Martin P., Bleyzac N., Souillet G., et al. Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation for matched-sibling or unrelated donors. Bone Marrow Transplant 2003, 22:881-887.
36. Ju M.K., Chang H.K., Kim H.J., et al. Is the affinity column-mediated immunoassay method suitable as an alternative to the microparticle immunoassay method as a blood tacrolimus assay?. Transplant Proc 2008, 40:3673-3678.
37. Ventura E., Bonardet A., Pageaux G.P., Mourad G., Cristol J.P. Calcineurin inhibitor determination in whole blood with the RXL dimension analyzer: a useful tool for immunosuppressive drug monitoring. Transplant Proc 2009, 41:707-709.
38. De B.K., Jimenez E., De S., Sawyer J.C., McMillin G.A. Analytical performance characteristics of the Abbott Architect i2000 Tacrolimus assay; comparisons with liquid chromatography-tandem mass spectrometry (LC-MS/MS) and Abbott IMx methods. Clin Chim Acta 2009, 410:25-30.
39. Wallemacq P., Goffinet J.-S., O'Morchoe S., et al. Multi-site analytical evaluation of the Abbott ARCHITECT tacrolimus assay. Ther Drug Monit 2009, 31:198-204.
40. Moscato D., Nonnato A., Adamo R., Vancheri M., Caropreso A. Therapeutic drug monitoring of tacrolimus: aberrant results by an immunoassay with automated pretreatment. Clin Chim Acta 2010, 411:77-80.
41. Hermida J., Tutor J.C. Falsely increased blood tacrolimus concentrations using the ACMIA assay due to circulating endogenous antibodies in a liver transplant recipient: a tentative approach to obtaining reliable results. Ther Drug Monit 2009, 31:269-272.
42. Rostaing L., Cointault O., Marquet P., et al. Falsely elevated whole-blood tacrolimus concentrations in a kidney-transplant patient: potential hazards. Transpl Int 2010, 23:227-230.
43. Cogill J.L., Taylor P.J., Westley I.S., et al. Evaluation of the tacrolimus II microparticle enzyme immunoassay (MEIA II) in liver and renal transplant recipients. Clin Chem 1998, 44:1942-1946.
44. Ghoshal A.K., Soldin S.J. IMx tacrolimus II assay: is it reliable at low blood concentrations? A comparison with tandem MS/MS. Clin Biochem 2002, 35:389-392.
45. Westley I.S., Taylor P.J., Salm P., et al. Cloned enzyme donor immunoassay tacrolimus assay compared with high-performance liquid chromatography-tandem mass spectrometry and microparticle enzyme immunoassay in liver and renal transplant recipients. Ther Drug Monit 2007, 29:584-591.